Cosmetic “blacklist” in China
This article was originally published in The Rose Sheet
Executive Summary
The Chinese Ministry of Health has "blacklisted" 10 domestically-made cosmetics, alleging that they contain ingredients that make the skin waste away and become discolored and more susceptible to disease, wire services report. The items contain dexamethasone, which makes the skin seem improved initially but can cause it to appear thin and dark and waste away over time. After consumers stop using products containing the ingredient, the skin becomes dry and develops rashes, the Ministry of Health says. The ingredient has been found in nine types of lotions, anti-allergy essences and masks produced by the Guangzhou Shimei Cosmetics Co. Ltd., as well as an anti-allergy moisture mask sold by Gelamei Cosmetic Co. Ltd. Both firms are located in Guandong Province. The Chinese Ministry of Health did not indicate whether recalls of the products are required or if the items have been exported, wire services say. Alerts related to unsafe personal-care and other products from China have become increasingly frequent; recently, U.S. Customs and Border Protection officers seized tubes of toothpaste exported from China that were adulterated with diethylene glycol (1"The Rose Sheet" Oct. 8, 2007, In Brief). The Chinese government has pledged to crack down on the problem...
You may also be interested in...
CBP seizes toothpaste
U.S. Customs and Border Protection officers in Charleston, S.C. announce Oct. 3 they have seized 1,440 tubes of toothpaste adulterated with antifreeze ingredient diethylene glycol (DEG). CBP says the toothpaste has deceptive country-of-origin markings: Shrink-wrap on the outside of the boxes is marked "made in China" while the boxes themselves are marked "made in India." The agency says officers performed an initial examination of the shipment in July and sent samples to a lab where they tested positive for DEG. China has banned firms in the country from using DEG as a toothpaste ingredient after FDA discovered DEG in multiple Chinese-manufactured products and in June ordered the detention without physical examination of all dentifrice products containing DEG (1"The Rose Sheet" June 11, 2007, p. 8)...
Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking
Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.